How long after a herpes zoster (shingles) outbreak should I wait to get the Shingrix (recombinant zoster vaccine) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timing of Shingrix Vaccination After a Shingles Outbreak

Wait at least 2 months after a shingles outbreak before receiving the Shingrix (recombinant zoster vaccine). 1

Rationale for the 2-Month Waiting Period

  • The 2-month interval recommendation is based on documented evidence showing this is the minimum interval between an episode of herpes zoster and potential recurrence 1
  • This waiting period allows for complete resolution of acute symptoms and recovery of the immune system to optimize vaccine response 1
  • Vaccination should occur once the acute symptoms have resolved, typically waiting at least 2 months after the episode 2

Vaccination Schedule After Shingles

  • For immunocompetent adults, Shingrix is administered as a two-dose series with the second dose given 2-6 months after the first dose 2
  • For immunocompromised adults aged ≥18 years, a shorter schedule with the second dose given 1-2 months after the first dose is recommended 3, 2
  • The minimum interval between doses is 4 weeks; if administered earlier than this minimum interval, the dose should be repeated 2

Importance of Vaccination After Shingles

  • Having one episode of shingles does not provide reliable protection against future recurrences 2
  • A recent US study showed a cumulative incidence of shingles recurrence of 2.5% at 2 years, increasing to 10.3% at 10 years 1
  • Vaccination after a shingles outbreak is particularly important due to this significant risk of recurrence 2

Vaccine Efficacy

  • Shingrix demonstrates high efficacy in preventing herpes zoster with vaccine efficacy of 97.2% in adults aged 50 years and older 2
  • Protection persists for at least 8 years with minimal waning, maintaining efficacy above 83.3% during this period 2
  • Real-world effectiveness studies show approximately 70.1% effectiveness for 2 doses and 56.9% for 1 dose 4

Special Considerations

  • For patients who have previously received the live-attenuated herpes zoster vaccine (Zostavax), Shingrix should be given at least 2 months after the last Zostavax dose 3, 2
  • For recipients of autologous hematopoietic stem cell transplant (HSCT), Shingrix should be given 50-70 days post-transplantation 2
  • Shingrix is the preferred vaccine for adults who have experienced a shingles outbreak, as it provides superior efficacy compared to the older live-attenuated vaccine 2, 5

Country-Specific Variations

  • Different countries have varying recommendations for the time frame between a shingles episode and vaccination: USA and Germany recommend waiting until the acute stage has resolved, Austria recommends waiting at least 2 months, while Canada, Ireland, and Australia recommend waiting at least 1 year 1

Common Pitfalls to Avoid

  • Waiting too long after the 2-month minimum period can increase the risk of recurrence 1
  • Confusing the waiting period after shingles with the interval between vaccine doses 1
  • Missing the opportunity for vaccination in older adults who have had shingles, as they remain at risk for recurrence 1
  • Assuming that starting antiviral therapy immediately makes the patient non-contagious - viral shedding continues until lesions are fully crusted 6

References

Guideline

Timing of Shingles Vaccination After a Shingles Outbreak

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

SHINGRIX Vaccination Schedule for Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021

Research

Summary of the NACI Update on Herpes Zoster Vaccines.

Canada communicable disease report = Releve des maladies transmissibles au Canada, 2018

Guideline

Herpes Zoster Contagiousness and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.